Open38.810 | Close39.130 |
Vol / Avg.3.046M / 2.187M | Mkt Cap5.661B |
Day Range38.470 - 40.900 | 52 Wk Range12.420 - 44.190 |
Immunovant Stock (NASDAQ: IMVT) stock price, news, charts, stock research, profile.
Open38.810 | Close39.130 |
Vol / Avg.3.046M / 2.187M | Mkt Cap5.661B |
Day Range38.470 - 40.900 | 52 Wk Range12.420 - 44.190 |
Q3 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.480 | -0.450 | 0.0300 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-11-15 | Truist Securities | Robyn Karnauskas | Maintains | BuyBuy | Raises | 30.00 | 48.00 |
2023-10-24 | Piper Sandler | Yasmeen Rahimi | Maintains | OverweightOverweight | Raises | 28.00 | 57.00 |
2023-10-24 | HC Wainwright & Co. | Douglas Tsao | Maintains | BuyBuy | Raises | 29.00 | 47.00 |
2023-10-16 | Cantor Fitzgerald | Louise Chen | Maintains | OverweightOverweight | Raises | 30.00 | 45.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMVT | Immunovant | 2.33% | 5.7B |
LEGN | Legend Biotech | 2.83% | 11.2B |
EXAS | Exact Sciences | -1.63% | 11.6B |
SRPT | Sarepta Therapeutics | 1.37% | 7.6B |
NBIX | Neurocrine Biosciences | 2.69% | 11.5B |
You can purchase shares of Immunovant (NASDAQ: IMVT) through any online brokerage.
Other companies in Immunovant’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Immunovant (NASDAQ: IMVT) was reported by Truist Securities on Wednesday, November 15, 2023. The analyst firm set a price target for 48.00 expecting IMVT to rise to within 12 months (a possible 22.67% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Immunovant (NASDAQ: IMVT) is $39.13 last updated November 30, 2023 at 9:33 PM UTC.
There is no dividend information for Immunovant.
Immunovant’s Q3 earnings are confirmed for Friday, February 2, 2024.
There is no upcoming split for Immunovant.
Immunovant is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.